Lilly's 14th acquisition of the year is a little-known blood cancer biotech
Eli Lilly has been on a shopping spree this year thanks to its GLP-1-driven revenue, and its 14th acquisition of 2026 is in cancer, the domain of expertise for the pharma's head ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.